AtriCure (AtriCure) Cash-to-Debt

: 1.84 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AtriCure's cash to debt ratio for the quarter that ended in Dec. 2023 was 1.84.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, AtriCure could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for AtriCure's Cash-to-Debt or its related term are showing as below:

ATRC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.92 Med: 1.73 Max: 14.71
Current: 1.84

During the past 13 years, AtriCure's highest Cash to Debt Ratio was 14.71. The lowest was 0.92. And the median was 1.73.

ATRC's Cash-to-Debt is ranked worse than
51.16% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs ATRC: 1.84

AtriCure Cash-to-Debt Historical Data

The historical data trend for AtriCure's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AtriCure Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

1.07

3.30

1.57

1.63

1.84

AtriCure Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															1.63	1.81	1.70	1.79	1.84

Competitive Comparison

For the Medical Instruments & Supplies subindustry, AtriCure's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AtriCure Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AtriCure's Cash-to-Debt falls into.

AtriCure Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AtriCure's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	137.285	/	(2.533	+	71.961)
	=	1.84

AtriCure's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	137.285	/	(2.533	+	71.961)
	=	1.84

AtriCure (NAS:ATRC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

AtriCure Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AtriCure's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AtriCure (AtriCure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

7555 Innovation Way, Mason, OH, USA, 45040

Website

https://www.atricure.com

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Executives

Karl S. Dahlquist	officer: Chief Legal Officer	7555 INNOVATION WAY, MASON OH 45040
Karen Prange	director	1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy	officer: Chief Scientific Officer	7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount	officer: Chief Human Resources Officer	7555 INNOVATION WAY, MASON OH 45040
Tonya Austin	officer: Chief Human Resources Officer	7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick	officer: Chief Financial Officer	7555 INNOVATION WAY, MASON OH 45040
Mark A Collar	director	382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves	director	5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith	officer: SVP of Sales and Marketing	7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera	officer: VP; Product Development	7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky	officer: SVP, Mktg & Business Develop	7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake	director	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein	director